Despite significant investor interest, the company chose to limit the capital raise to SEK 60 million – a level that the Board of Directors believes provides Cereno Scientific with the financial strength and negotiating position required to advance ongoing partnering processes from a materially stronger position, it states. The capital strengthens the company’s negotiating position, secures continued strong momentum in its clinical and regulatory priorities, and increases the company’s ability to translate external interest in its development programs into tangible value-creating opportunities for shareholders.

”We are very pleased with the strong interest we have received in connection with the Directed Issue and would like to extend our sincere thanks to both existing and new shareholders for their strong confidence. Despite significant interest, we chose to carry out a relatively limited capital raise, as it provides us with the flexibility we need to continue driving our ongoing partnering processes forward with increased strength, pace and negotiating power,” says Sten R. Sörensen, CEO and Board member of Cereno Scientific. “We have active and constructive dialogues with several external parties. We have also just returned from the BIO International Convention in San Diego, where we held a large number of meetings with both parties that we have met several times before and new potential partners. Interest in Cereno Scientific and our pipeline has never been stronger, and our absolute focus is now to translate this momentum into tangible value-creating deals for the Company and our shareholders. As I have previously communicated, I believe that Cereno Scientific continues to move closer to a significant value-creating step. This financing strengthens our position in that work and gives us the conditions to drive the processes forward with strength, discipline and a clear shareholder focus.”

“The Board views this directed issue as a proactive step that strengthens Cereno Scientific ahead of a decisive phase. The transaction is carried out at a premium to the latest closing price and with limited dilution, which we view as a clear expression of investors’ confidence in the Company’s position and potential. Through the financing, the Company’s ability to act with pace, discipline and strength in ongoing processes increases, while we can continue to prioritize capital where it has the greatest potential to create shareholder value. The capital strengthens our starting point in both clinical execution and business development and gives the Company better conditions to drive strategic discussions on terms that reflect the significant potential of the development programs. We appreciate the continued support from existing shareholders and welcome a new investor, while remaining fully focused on disciplined capital allocation and value creation,” says Jeppe Øvlesen, Chairman of the Board of Cereno Scientific.